UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 102

Sortiert nach

Targeting the folate receptor: diagnostic and therapeutic approaches to personalize cancer treatments

Annals of oncology, 2015-10, Vol.26 (10), p.2034-2043

2015

Link zum Volltext

Verfügbarkeit prüfen

PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies

Annals of oncology, 2014-01, Vol.25 (1), p.32-40

2014

Link zum Volltext

Verfügbarkeit prüfen

Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

Annals of oncology, 2022-09, Vol.33 (9), p.860-877

2022

Link zum Volltext

Verfügbarkeit prüfen

Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Annals of oncology, 2013-10, Vol.24 Suppl 6, p.vi24-vi32

2013

Link zum Volltext

Verfügbarkeit prüfen

ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer

Annals of oncology, 2020-12, Vol.31 (12), p.1606-1622

2020

Link zum Volltext

Verfügbarkeit prüfen

The systemic treatment of recurrent ovarian cancer revisited

Annals of oncology, 2021-06, Vol.32 (6), p.710-725

2021

Link zum Volltext

Verfügbarkeit prüfen

Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline

Annals of oncology, 2023-01, Vol.34 (1), p.33-47

2023

Link zum Volltext

Verfügbarkeit prüfen

Optimal first-line treatment in ovarian cancer

Annals of oncology, 2012-09, Vol.23 Suppl 10, p.x118-x127

2012

Link zum Volltext

Verfügbarkeit prüfen

Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: first-line interventions

Annals of oncology, 2017-04, Vol.28 (4), p.711-717

2017

Link zum Volltext

Verfügbarkeit prüfen

Platinum versus platinum-combination chemotherapy in platinum-sensitive recurrent ovarian cancer: a meta-analysis using individual patient data

Annals of oncology, 2013-12, Vol.24 (12), p.3028-3034

2013

Link zum Volltext

Verfügbarkeit prüfen

PARP inhibitors in ovarian cancer

Annals of oncology, 2016-04, Vol.27 Suppl 1 (suppl_1), p.i40-i44

Ledermann, J A

2016

Link zum Volltext

Verfügbarkeit prüfen

Primary tumour resection and survival in the palliative management of metastatic colorectal cancer

European journal of surgical oncology, 2009-02, Vol.35 (2), p.164-167

2009

Link zum Volltext

Verfügbarkeit prüfen

Small cell of the ovary, hypercalcemic type—Analysis of combined experience and recommendation for management. A GCIG study

Gynecologic oncology, 2006-02, Vol.100 (2), p.233-238

2006

Link zum Volltext

Verfügbarkeit prüfen

Updated treatment recommendations for newly diagnosed epithelial ovarian carcinoma from the ESMO Clinical Practice Guidelines

Annals of oncology, 2021-10, Vol.32 (10), p.1300-1303

2021

Link zum Volltext

Verfügbarkeit prüfen

Treatment with olaparib monotherapy in the maintenance setting significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: Results from the phase III SOLO2 study

Gynecologic oncology, 2017-06, Vol.145, p.219-220

2017

Link zum Volltext

Verfügbarkeit prüfen

Latest clinical evidence and further development of PARP inhibitors in ovarian cancer

Annals of oncology, 2018-06, Vol.29 (6), p.1366-1376

2018

Link zum Volltext

Verfügbarkeit prüfen

Front-line therapy of advanced ovarian cancer: new approaches

Annals of oncology, 2017-11, Vol.28 (suppl_8), p.viii46-viii50

Ledermann, J A

2017

Link zum Volltext

Verfügbarkeit prüfen

2748 Assessment of associations between disease stage and toxicity with bevacizumab (BEV) in ICON7, a phase III trial of front-line carboplatin/paclitaxel (CP) ± BEV for ovarian cancer (OC)

European journal of cancer (1990), 2015-09, Vol.51, p.S546-S546

2015

Link zum Volltext

Verfügbarkeit prüfen

Analysis of intermediate clinical endpoints from a Phase II trial of olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC)

Gynecologic oncology, 2014-06, Vol.133, p.54-55

2014

Link zum Volltext

Verfügbarkeit prüfen

Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study

Annals of oncology, 2019-07, Vol.30 (7), p.1080-1087

2019

Link zum Volltext

Verfügbarkeit prüfen

Progress in Ovarian Cancer Treatment Through GCIG Collaborative Trials

Annals of oncology, 2012-10, Vol.23, p.xi9

Ledermann, J.A.

2012

Link zum Volltext

Verfügbarkeit prüfen

Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004)

Annals of oncology, 2012-10, Vol.23 (10), p.2619-2626

2012

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial

Annals of oncology, 2022-10, Vol.33 (10), p.1021-1028

2022

Link zum Volltext

Verfügbarkeit prüfen

Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

Annals of oncology, 2023-10, Vol.34 (10), p.833-848

2023

Link zum Volltext

Verfügbarkeit prüfen

Optimal treatment for relapsing ovarian cancer

Annals of oncology, 2010-10, Vol.21 (suppl-7), p.vii218-vii222

2010

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 102

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(101)
Mit Volltextzugriff
(101)

Publikationsform

Artikel
(102)

Sprache

Englisch
(102)
Japanisch
(12)

Erscheinungsjahr

n.n

Thema

Humans
(43)
Life Sciences & Biomedicine
(43)
Science & Technology
(43)
Oncology
(41)
Female
(34)
Ovarian Neoplasms - Drug Therapy
(20)
Middle Aged
(16)
Ovarian Cancer
(16)
Adult
(15)
Aged
(15)
Biological And Medical Sciences
(15)
Medical Sciences
(15)
Pharmacology. Drug Treatments
(13)
Tumors
(13)
Antineoplastic Agents
(12)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(12)
Disease-Free Survival
(11)
Prognosis
(11)
Hematology
(10)
Ovarian Neoplasms - Pathology
(10)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Targeting the folate receptor: diagnostic and therapeutic approaches to personalize cancer treatments

PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies

Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer

The systemic treatment of recurrent ovarian cancer revisited

Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline

Optimal first-line treatment in ovarian cancer

Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: first-line interventions

Platinum versus platinum-combination chemotherapy in platinum-sensitive recurrent ovarian cancer: a meta-analysis using individual patient data

PARP inhibitors in ovarian cancer

Primary tumour resection and survival in the palliative management of metastatic colorectal cancer

Small cell of the ovary, hypercalcemic type—Analysis of combined experience and recommendation for management. A GCIG study

Updated treatment recommendations for newly diagnosed epithelial ovarian carcinoma from the ESMO Clinical Practice Guidelines

Treatment with olaparib monotherapy in the maintenance setting significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: Results from the phase III SOLO2 study

Latest clinical evidence and further development of PARP inhibitors in ovarian cancer

Front-line therapy of advanced ovarian cancer: new approaches

2748 Assessment of associations between disease stage and toxicity with bevacizumab (BEV) in ICON7, a phase III trial of front-line carboplatin/paclitaxel (CP) ± BEV for ovarian cancer (OC)

Analysis of intermediate clinical endpoints from a Phase II trial of olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC)

Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study

Progress in Ovarian Cancer Treatment Through GCIG Collaborative Trials

Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004)

Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial

Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

Optimal treatment for relapsing ovarian cancer

Suchergebnisse filtern